Friday 6 November 2026
Export PBH’s income statement to Excel — free account
Prestige Consumer Healthcare Inc.
PBH Healthcare Drug Manufacturers Specialty & Generic
Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.
- Revenue
- +22.7%
- EPS
- −38.4%
- Free cash flow
- −38.2%
- Total debt
- +100.9%
Quarter to September 2026, against a year earlier
43.42
0.90
−2.03%
Follow PBH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
16.19 | 15.04 | 13.17 | 14.07 |
P/S ratio |
2.68 | 2.64 | 2.03 | 1.87 | |
P/FCF ratio |
11.05 | 11.65 | 9.53 | 10.17 | |
P/Operating CF |
37.73 | 67.04 | 31.69 | 57.54 | |
P/B ratio |
1.61 | 1.52 | 1.17 | 1.12 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.58 | 3.52 | 3.79 | 3.57 | |
EV/EBITDA |
11.16 | 11.18 | 12.92 | 12.59 | |
EV/Operating CF |
14.29 | 14.87 | 16.80 | 18.13 | |
EV/FCF |
14.80 | 15.54 | 17.80 | 19.45 | |
Quick Ratio |
1.81 | 2.12 | 1.80 | 1.72 | |
Current Ratio |
3.11 | 3.57 | 3.23 | 2.92 | |
Net Debt/EBITDA |
10.93 | 11.25 | 31.52 | (0.49) | |
Debt/Assets |
30.11% | 28.96% | 44.54% | 0.00% | |
Debt/Equity |
0.58 | 0.54 | 1.06 | 0.00 | |
Asset Turnover |
0.32 | 0.32 | 0.28 | 0.29 | |
Operating CF/Net income |
1.68 | 0.79 | 2.43 | 1.50 | |
Capex/Depreciation |
(0.38) | (0.59) | (0.40) | (0.27) | |
Interest Coverage |
7.73 | 6.61 | 3.77 | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
24.60% | 23.21% | 29.34% | 24.72% | |
Intangible Assets out of Total Assets |
0.82 | 0.82 | 0.85 | 0.86 | |
Share Based Compensation of Revenue |
0.97% | 0.94% | 1.50% | 0.37% | |
Graham Net Nets |
(0.42) | (0.41) | (0.96) | (1.05) | |
Graham Number |
57.23 | 58.76 | 57.11 | 54.80 | |
Earnings Yield |
6.18% | 6.65% | 7.59% | 7.11% | |
Free Cash Flow Yield |
9.05% | 8.58% | 10.49% | 9.83% | |
Revenue per Share |
5.92 | 5.81 | 5.60 | 7.08 | |
Operating CF per Share |
1.64 | 0.88 | 1.49 | 0.80 | |
Capex per Share |
(0.06) | (0.11) | (0.08) | (0.08) | |
Free Cash Flow per Share |
1.57 | 0.78 | 1.41 | 0.72 | |
Cash per Share |
1.30 | 1.32 | 1.88 | 0.98 | |
Shareholders Equity per Share |
38.21 | 38.95 | 40.38 | 40.94 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
38.21 | 38.95 | 40.38 | 40.94 | |
Free Cash Flow |
75.26 | 37.63 | 67.09 | 34.24 | |
Working Capital |
293.87 | 310.56 | 343.01 | 323.63 | |
Capital Expenditures |
(3.03) | (5.21) | (3.70) | (3.62) | |
Net Current Asset Value |
(1,231.86) | (1,175.31) | (2,155.04) | (2,284.87) | |
EV/EBIT |
12.26 | 12.38 | 14.44 | 14.31 | |
Capex to Sales |
0.01 | 0.02 | 0.01 | 0.01 | |
Price to Operating Income |
9.16 | 9.28 | 7.73 | 7.48 | |
| Other line items | |||||
Average Receivables |
178.87 | 193.11 | 177.88 | 221.56 | |
Average Payables |
31.23 | 20.86 | 29.53 | 42.97 | |
Average Inventory |
157.56 | 153.42 | 171.67 | 169.10 | |
Average Assets |
3,412.12 | 3,448.27 | 4,000.10 | 4,081.97 | |
Average Common Equity |
1,808.94 | 1,861.21 | 1,886.10 | 1,884.82 |
Columns are period end dates · fundamentals updated 5 Nov 2026